Effectiveness of Immune Checkpoint Inhibitor with Anti-PD-1 Monotherapy or in Combination with Ipilimumab in Younger versus Older Adults with Advanced Melanoma

Autor: Taylor E. Woo, Igor Stukalin, Philip Q. Ding, Siddhartha Goutam, Michael Sander, Benjamin Ewanchuk, Winson Y. Cheung, Daniel Y. C. Heng, Tina Cheng

Publikováno v: Current Oncology, Vol 30, Iss 10, Pp 8936-8947 (2023)

Background: The majority of melanoma is diagnosed in individuals between 55 and 84 years old. Current data varied in reporting differences in survival outcomes amongst different age groups. Methods: A retrospective, multi-center, provincial cohort da

Externí odkaz: https://doaj.org/article/d3356bccbd954bebb8c1372aca614954

Real-world Outcomes of Ipilimumab Plus Nivolumab Combination Therapy in a Nation-wide Cohort of Advanced Melanoma Patients in the Netherlands

Autor: van Zeijl, Michiel C T, van Breeschoten, Jesper, de Wreede, Liesbeth C, Wouters, Michel W J M, Hilarius, Doranne L, Blank, Christian U, Aarts, Maureen J B, van den Berkmortel, Franchette W P J, de Groot, Jan Willem B, Hospers, Geke A P, Kapiteijn, Ellen, Piersma, Djura, van Rijn, Rozemarijn S, Stevense-den Boer, Marion A, van der Veldt, Astrid A M, Vreugdenhil, Gerard, Boers-Sonderen, Marye J, Suijkerbuijk, Karijn P M, Haanen, John B A G, van den Eertwegh, Alfons J M

Publikováno v: Journal of Immunotherapy (1997), 46, 197-204
van Zeijl, M C T, van Breeschoten, J, de Wreede, L C, Wouters, M W J M, Hilarius, D L, Blank, C U, Aarts, M J B, van den Berkmortel, F W P J, de Groot, J W B, Hospers, G A P, Kapiteijn, E, Piersma, D, van Rijn, R S, Stevense-den Boer, M A, van der Veldt, A A M, Vreugdenhil, G, Boers-Sonderen, M J, Suijkerbuijk, K P M, Haanen, J B A G & van den Eertwegh, A J M 2023, ' Real-world Outcomes of Ipilimumab Plus Nivolumab Combination Therapy in a Nation-wide Cohort of Advanced Melanoma Patients in the Netherlands ', Journal of Immunotherapy, vol. 46, no. 5, pp. 197-204 . https://doi.org/10.1097/CJI.0000000000000468
Journal of Immunotherapy (1997), 46, 5, pp. 197-204
Journal of Immunotherapy, 46(5), 197-204. Lippincott Williams and Wilkins
Journal of Immunotherapy, 46(5), 197-204. Lippincott Williams & Wilkins

Item does not contain fulltext In phase III trials, ipilimumab plus nivolumab combination therapy is highly efficacious for advanced melanoma, despite many treatment-related grades 3-4 adverse events. Here, we report real-world safety and survival ou

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fc5cae1f59afc7919e206ea2bb7ce20f
https://cris.maastrichtuniversity.nl/en/publications/0bab63c2-7c57-472e-b6fd-b12fcc4f0a81

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.